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Serology reflects a decline in the 
prevalence of trachoma in two 
regions of The Gambia
Stephanie J. Migchelsen  1, Nuno Sepúlveda1,2, Diana L. Martin3, Gretchen Cooley3, Sarah 
Gwyn4, Harry Pickering1, Hassan Joof5, Pateh Makalo5, Robin Bailey1, Sarah E. Burr1,5, David 
C. W. Mabey1, Anthony W. Solomon1 & Chrissy h. Roberts  1
Trachoma is caused by Chlamydia trachomatis (Ct). It is targeted for global elimination as a public health 
problem. In 2014, a population-based cross-sectional study was performed in two previously trachoma-
endemic areas of The Gambia. Participants of all ages from Lower River Region (LRR) (N = 1028) and 
Upper River Region (URR) (N = 840) underwent examination for trachoma and had blood collected 
for detection of antibodies against the Ct antigen Pgp3, by ELISA. Overall, 30 (1.6%) individuals had 
active trachoma; the prevalence in children aged 1–9 years was 3.4% (25/742) with no statistically 
significant difference in prevalence between the regions. There was a significant difference in overall 
seroprevalence by region: 26.2% in LRR and 17.1% in URR (p < 0.0001). In children 1–9 years old, 
seroprevalence was 4.4% in LRR and 3.9% in URR. Reversible catalytic models using information on 
age-specific seroprevalence demonstrated a decrease in the transmission of Ct infection in both regions, 
possibly reflecting the impact of improved access to water, health and sanitation as well as mass drug 
administration campaigns. Serological testing for antibodies to Ct antigens is potentially useful for 
trachoma programmes, but consideration should be given to the co-endemicity of sexually transmitted 
Ct infections.
Trachoma is caused by ocular infection with the obligate intracellular bacterium Chlamydia trachomatis (Ct). It 
is the leading infectious cause of blindness worldwide1. Infection is associated with clinical signs of inflammation 
in the conjunctiva, known as active trachoma; these include trachomatous inflammation—follicular (TF) and 
trachomatous inflammation—intense (TI). Many repeated episodes of active trachoma over years to decades can 
lead to trachomatous trichiasis (TT), which may lead to impaired vision. The World Health Organization (WHO) 
estimates that over 200 million people in 42 countries are at risk of blindness from trachoma2. In 2010, approxi-
mately 1.9 million people suffered from visual impairment or blindness due to trachoma1. The WHO Alliance for 
the Global Elimination of Trachoma by 2020 (GET2020) aims to eliminate trachoma as a public health problem 
by 20202 through the SAFE Strategy (Surgery, Antimicrobials, Facial cleanliness and Environmental improve-
ment). The WHO-endorsed strategy for global control is to reduce the population prevalence of TF to <5% in 
children aged 1–9 years and the prevalence of unmanaged TT to <0.2% in adults aged 15 years and above3. By 
2014, seven countries had reported having met these targets nationally4. The Gambia has been a hub for trachoma 
research for over 50 years and is on course to declare the elimination of trachoma as a public health problem by 
2020. Two National Surveys of Blindness and Low Vision in The Gambia demonstrated that there had been a 
nation-wide decrease in the prevalence of active trachoma and TT between 1986 and 20005,6. Specific elimination 
efforts, undertaken between 2007 and 2010 and run by the National Eye Health Programme (NEHP), included 
mass drug administration (MDA) of azithromycin in 23 districts across the country. The Partnership for the 
Rapid Elimination of Trachoma (PRET)7 was embedded within the national programme and measured the prev-
alence of Ct infection in children residing in four districts in which MDA had been administered. Deployment 
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of interventions and disease control measures across The Gambia was not even, with some districts receiving the 
full SAFE intervention and others receiving reduced (F & E components) or no specifically targeted interventions. 
It is important to be able to evaluate the effectiveness of these interventions and a significantly reduced or halted 
transmission of infection is a key indicator that elimination may have been achieved.
The current guidelines for post-intervention surveillance of Ct transmission intensity are based on the 
prevalence of TF in children aged 1–9 years. This is problematic because in the peri-elimination period and 
low-endemicity settings7,8 the correlation between the clinical signs of trachoma and the presence of ocular Ct 
infection is poor. This diminishment of the positive predictive value of clinical signs means that the false positive 
rate of TF screening is increased and the specificity of the clinical sign is negatively affected.
Reduced global endemicity also leads to the unmasking of diseases that resemble trachoma clinically but 
which have no clear link to Ct infections. We recently surveyed the western division of the Solomon Islands9, a 
population where TF was not found to be a highly specific indicator of ocular Ct infection. Around 26% of 1–9 
year olds living there had TF, but Ct infection was very scarce at just 1.3%. Using a serological tool we showed that 
53/66 (80%) of the cases of TF that we observed were in people who were serologically negative for prior Ct infec-
tion10. Clinical signs of trachoma were also a poor indicator for the need to deploy antimicrobials in Fiji, where 
the high prevalence of TT cases could be better explained by socio-epidemiological practices of eyelash depilation 
than by Ct infections11. The current WHO guidelines would recommend MDA in both Fiji and the Solomon 
Islands, but the evidence from more detailed surveys makes an argument against the likelihood that the use of 
antimicrobials would be effective. Situations such as this highlight the need to develop new tools that can sup-
port programmes to make informed decisions about how to use antimicrobials in trachoma control. Antibodies 
against Chlamydia trachomatis reflect cumulative exposure to Ct12,13 and it has been suggested that programmes 
could use some measure of seroprevalence as an alternative indicator of changes in transmission14,15. Previous 
work has investigated the use of age-specific seroprevalence for surveillance in the peri-16 and post-MDA set-
ting15,17,18. Serological techniques for the detection of antibodies against Ct have been used to study the epidemi-
ology of both urogenital and ocular Ct infections19,20. An enzyme-linked immunoassay (ELISA) which detects 
antibodies against Pgp3 (pCT03) has recently been used for analysis of samples collected from trachoma-endemic 
regions21,22. The Pgp3 molecule is an immunogenic Ct-specific protein that is encoded by the Ct plasmid and 
which is highly conserved at the genetic level among Ct isolates23.
In the current study we have used serological data from a Pgp3-specific ELISA to gain insight into the dynam-
ics of Ct transmission in two regions of The Gambia, one of which (the Lower River Region [LRR]) had received 
three annual rounds of MDA, whilst the other (the Upper River Region [URR]) had not. URR was not targeted 
for antimicrobial use because the TF prevalence had already dropped below the WHO threshold for elimination 
as a public health problem.
To explore the utility of serology as a tool for surveillance in trachoma elimination programmes, we have 
modelled the seroconversion rate (SCR) in URR and LRR under different epidemiological settings. The SCR is the 
yearly average rate by which seronegative individuals become seropositive because of disease exposure. SCR is a 
metric that acts as a surrogate measure for the underlying force of infection (FoI) and the age specific SCR can be 
used to model changes in FOI across time, potentially identifying periods in which there were substantial changes 
in the rate of transmission of Ct infection in the population.
Results
We recruited participants of all ages from LRR (n = 1028, 41.9% male) and URR (n = 840, 42.5% male). Ten 
participants were excluded from the study because they either declined to provide a blood sample (n = 1) or had 
incomplete examination data (n = 9). The median participant age was 13 years in LRR (range: 1–88, IQR 6–34) 
and 11 years in URR (range: 0–90, IQR 5–40). The proportion of participants by age group is shown in Table 1. 
There were significantly more females than males overall (X2 = 45.332, p < 0.0001), which held true in both LRR 
(Χ2 = 26.483, p < 0.0001) and URR (X2 = 18.601, p < 0.0001) and is representative of Gambian demographics24. 
Age distributions were approximately equal between the two regions, as seen in Table 1 (Χ2 = 27.703, p = 0.14).
Both Regions Lower River Region Upper River Region
N % N % N %
Overall 1832 1010 55.1 822 44.9
Gender
Female 1056 57.7 584 58.0 472 57.0
Male 776 42.2 426 42.0 350 43.0
Age group (years)
1–9 742 39.7 383 37.3 359 42.7
10–19 412 22.1 231 22.5 181 21.5
20-29 191 10.2 101 9.8 90 10.7
30-39 152 8.1 79 7.7 73 8.7
40+ 335 17.9 216 21.0 119 14.2
Table 1. Age distribution of study participants, Lower River Region and Upper River Region, The Gambia, 
2014.
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Clinical signs. Thirty cases of TF were found in total (1.6%, 95% CI = 1.1–2.3%), of which 25 were in children 
aged 1–9 years (3.4%, 95% CI = 2.2–4.9, Table 2). There were 78 cases of trachomatous conjunctival scarring (TS), 
of which 70 were in participants aged 15 years and above (8.3%, 95%CI = 6.6–10.5); eight cases of TT, all of which 
were in those aged 40 years and older (0.9%, 95% CI = 0.4–1.8); and one case of corneal opacity (CO), in a par-
ticipant over 40 years of age (0.1%, 95% CI = 0.0–0.6) (Table 2). The prevalence of TS was significantly different 
(Χ2 = 7.7932, p = 0.005) between LRR (5.4%, 95% CI = 4.1–7.1%) and URR (2.8%, 95% CI = 1.8–4.2%). The TF 
prevalence in children aged 1–9 years was not significantly different (Χ2 = 0.199, p = 0.66) between LRR (3.7%, 
95% CI = 2.1–6.2%) and URR (3.1%, 95%CI = 1.6–5.6%). The prevalence of TI, TT and CO in this population 
was too low for further statistical analysis.
Data from this study show very low prevalence of active trachoma in these regions. In children aged 1–9 years, 
only 4.2% had detectable antibodies against Pgp3. In both regions, the prevalence of TF in 1–9-year-olds was 
below the 5% threshold for elimination as a public health problem as specified by the WHO.
Antibody responses in the populations. The threshold for seropositivity was set using a finite mix-
ture model25 to classify the samples as seropositive or seronegative based on maximum likelihood methods. The 
threshold was set at the mean of the Gaussian distribution of the seronegative population plus four standard devi-
ations, 0.810 OD450nm to ensure high specificity. Previous studies using the Pgp3 ELISA have commonly used a 
threshold set as three standard deviations above the mean of the negative population (the 97.5% confidence inter-
val)21,26. Using that lower threshold resulted in the same qualitative conclusions being drawn (See Supplementary 
Information).
The seroprevalence of antibodies against Pgp3 for each region, by age and gender, is summarised in Table 3. 
The overall seroprevalence in LRR and URR was 26.2% (95% CI = 23.5–29.0) and 17.1% (95% CI = 14.7–19.9%), 
respectively. Adjusting for multiple comparisons, there was a significant difference in overall seropreva-
lence between the two regions (Χ2 = 20.72, p < 0.0001). Figure 1 shows the seroprevalence by age group and 
region. In children 1–9 years old, seroprevalence was 4.4% in LRR and 3.9% in URR. As expected, the prev-
alence of anti-Pgp3 antibodies increased with age using the non-parametric test for trend (z-score = 23.35, 
p < 0.0001; alpha = 0.01). The seroprevalence doubled between 10–19-year-olds and the next oldest age group, 
20–29-year-olds, both in the two regions combined, and in each region. Across both regions, in study participants 
who had no signs of trachoma, seroprevalence was 21% (95% CI = 19–23). Of those who had active trachoma (TF 
and/or TI) (n = 30), 3% were seropositive (95% CI = 0.1–17) and of those who had scarring trachoma (TS and/or 
TT and/or CO in either eye; n = 122) 56% were seropositive (95% CI = 44–67).
The prevalence of antibodies was significantly higher in females than in males (z-score = 6.384, p < 0.0001). 
The same was true in each region (LRR: z-score = 4.881, p < 0.0001; URR: z-score = 4.114, p < 0.0001). When 
data were considered for each age group, the seropositivity difference between males and females was only sig-
nificant for 10–19-year-olds (z-score = 2.667, p = 0.0077) and 30–39-year-olds (z-score = 0.2551, p = 0.0107). 
Seroprevalence by gender and age group is shown in Fig. 2.
Frequency of signs (%)
N TF TI TS TT CO
Overall 1832 30 (1.6) 4 (0.2) 78 (4.3) 8 (0.4) 1 (0.1)
Region
LRR 1010 18 (1.8) 4 (0.4) 55 (5.4) 7 (0.7) 1 (0.1)
URR 822 12 (1.4) 0 23 (2.8) 1 (0.1) 0
Gender
Female 1056 10 (0.9) 3 (0.3) 52 (4.9) 5 (0.5) 1 (0.1)
Male 776 20 (2.5) 1 (0.1) 26 (3.4) 3 (0.4) 0
Age group (years)
1–9 742 25 (3.4) 2 (0.3) 7 (1.1) 0 0
10–19 412 4 (1.0) 1 (0.2) 2 (0.5) 0 0
20–29 191 0 0 1 (0.5) 0 0
30–39 152 1 (0.7) 1 (0.7) 5 (3.3) 0 0
40+ 335 0 0 63 (18.8) 8 (2.4) 1 (0.3)
1–9 year olds -LRR 383 14 (3.7) 2 (0.5) 1 (0.3) 0 0
1–9 year olds -URR 359 11 (3.1) 0 6 (1.7) 0 0
≥10 year olds-LRR 645 4 (0.6) 2 (0.3) 54 (8.4) 7 (1.1) 1 (0.2)
≥10 year olds-URR 481 1 (0.2) 0 17 (3.5) 1 (0.2) 0
Table 2. Frequency of signs of trachoma in study participants, Lower River Region and Upper River Region, 
The Gambia, 2014. TF = trachomatous inflammation—follicular; TI = trachomatous inflammation—intense; 
TS = trachomatous conjunctival scarring; TT = trachomatous trichiasis; CO = corneal opacity LRR = Lower 
River Region; URR = Upper River Region.
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Reduction in seroconversion rates over time. We used a reversible catalytic model together with the 
profile likelihood method to identify reductions in seroconversion rates (SCR) in both LRR and URR. The revers-
ible catalytic model is based on the premise that individuals transit between seropositive and seronegative states 
with specific average rates27. We compared three different models under which transmission dynamics might 
have changed across time. Our first model used the assumption that there had been a constant transmission, the 
second that there had at some point been an abrupt change in force of infection and the third that there had been 
a constant FOI to a point, after which it had decayed in a log-linear manner. We found that the model of abrupt 
change was most likely to explain the data we had observed in The Gambia. Abrupt reductions in SCRs were 
identified in both LRR and URR (Table 4 and Fig. 3) and these changes in SCR are estimated to have occurred 
respectively 23 and 16 years before data collection took place (Fig. 3). For LRR, the SCR would appear to have 
dropped from an incidence of 0.062 yearly events per person, to 0.010 yearly events per person. These estimates 
implied a putative 6.3-fold decrease in transmission intensity. In URR, the estimate of the past SCR dropped from 
Both Lower River Region Upper River Region
N n % 95% CI N n % 95% CI N n % 95% CI
Overall 1832 412 22.5 20.2–24.0 1010 268 26.5 23.5–29.0 822 144 17.5 14.7–19.9
Gender
Female 1056 295 27.9 24.8–30.2 584 190 32.5 28.8–36.5 472 105 22.2 18.6–26.3
Male 776 117 15.1 12.4–17.5 426 78 18.3 14.8–22.4 350 39 11.1 8.1–15.0
Age group (years)
1–9 742 31 4.2 2.9–5.9 383 17 4.4 2.6–7.0 359 14 3.9 2.1–6.5
10–19 412 48 11.7 8.7–15.1 231 29 12.6 8.6–17.5 181 19 10.5 6.4–16.0
20–29 191 48 25.1 19.1–31.9 101 28 27.7 19.3–37.5 90 20 22.2 14.1–32.2
30–39 152 73 48.0 39.9–56.3 79 41 51.9 40.4–63.3 73 32 43.8 32.2–55.9
40+ 335 212 63.3 57.9–68.5 216 153 70.8 64.3–76.8 119 59 49.6 40.3–58.9
Table 3. Seroprevalence of anti-Pgp3 antibodies by region, gender and age, Lower River Region and Upper 
River Region, The Gambia, 2014.
Figure 1. Proportion of participants who were seropositive for anti-Pgp3 antibodies by age group and region, 
Lower River Region (LRR) and Upper River Region (URR), The Gambia, 2014. Vertical bars indicate 95% CIs.
Figure 2. Proportion of participants who were seropositive for anti-Pgp3 antibodies, by age group and gender, 
Lower River Region and Upper River Region, The Gambia, 2014. Vertical bars indicate 95% confidence 
intervals.
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0.050 yearly events per person to 0.008 yearly events per person, a 3.2-fold decrease (Table 4). Figure 4 shows the 
expected seroprevalence curves as function of age assuming a change in transmission intensity.
Discussion
The Gambian government is currently compiling evidence for validation of trachoma elimination, following com-
pletion of its three-year TF/TT surveillance plan, which began in 201128,29. Previous studies have demonstrated 
declines in the prevalence of active trachoma in The Gambia both prior to8,30 and in response to the implemen-
tation of specific trachoma-control interventions31–33. Increased access to water, education and healthcare in The 
Gambia during recent decades are thought to have had an impact34, manifesting in a secular decline. Regardless 
of cause, the prevalence of active trachoma in 0–14-year-olds fell from 10.4% in 19866 to less than 5% in 19965 
and has subsequently remained low. Prevalence data from historical studies is presented in Table 5. More recently, 
six years before the survey reported here, communities in LRR received azithromycin to treat ocular Ct infection, 
further reducing the prevalence of trachoma in this region7,29, while communities in URR did not. Although not 
measured in our study, previous work has shown that there has been a reduction in the prevalence of ocular Ct 
infection in two villages in LRR35,36 with the most recent measurements showing 0.5% infection prevalence in 
PRET villages, a portion of which are in LRR7. In line with the findings of those previous studies, we provide a 
further data point showing TF prevalence <5% for each region. The prevalence of clinical signs strongly supports 
The Gambia’s claim to have eliminated trachoma as a public health problem from these areas. The seroprevalence 
estimates and FoI modelling of trachoma transmission intensity offer further support that transmission is greatly 
reduced and that trachoma is no longer a public health problem in the areas studied. Seroprevalence data pre-
sented here are very similar to those seen in a recent study in Tanzania, where ocular Ct infection was eliminated 
in 200537 and serology shows an equally low prevalence of antibodies against Ct in children15.
We used three SCR models to estimate the change in SCR: the first model assumed no change in SCR and 
serves as a baseline for the second and third models, both of which did assume a change in SCR. The best model 
allowed for an acute change in SCR (Table 4, Fig. 3).
Our analysis of age-specific seroprevalence suggests that the FOI is currently very low, with a substantial 
decrease in SCR in children having occurred approximately 20 years ago (compared to the children that grew up 
before then). This change is too acute to reflect secular decline in the FoI of trachoma and may indicate the effects 
of interventions.
Region SCRpast SCRcurrent SRR Fold change
Lower River Region 0.095 (0.051–0.176) 0.015 (0.012–0.019) 0.008 (0.004–0.015) 6.3
Upper River Region 0.038 (0.018–0.082) 0.012 (0.009–0.016) 0.011 (0.003–0.039) 3.2
Table 4. Maximum likelihood estimates for the past and current seroconversion and seroreversion rates (SCR 
and SRR, respectively) associated with data collected from participants in Lower River Region and Upper River 
Region, The Gambia, 2014 where the respective 95% confidence intervals are shown in brackets.
Figure 3. Akaike’s information criterion (AIC) using the profile likelihood method for estimating the change-
point for the models assuming an abrupt reduction in transmission intensity or annual log-linear decay 
of transmission intensity from the change-point to the present. In this analysis, the best model as function 
of change point is the one that leads to the minimum estimate of the AIC. Note that a change point of 0 is 
equivalent to the simple model assuming a constant transmission intensity over time. The results suggest abrupt 
reductions of transmission intensity 23 and 16 years before sampling for respectively the lower and upper river 
regions.
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One confounding factor in this analysis is that the serological test we used was not specific to ocular Ct infec-
tions; rather it indicates whether the individual being tested has antibodies against Ct that might originate from 
historical ocular or urogenital infections. Whilst the acute change in SCR that we identified would be consist-
ent with a significant drop in the transmission intensity of ocular Ct in the mid to late 1990s, it could also be 
explained by a confounding signal from contemporary seroconversion events that relate to sexual activity of 
people in their late teens to mid-twenties. It is arguably most likely that the data reflect both things, but without 
current data describing the population prevalence of urogenital and ocular infections, the proportional contribu-
tions of STIs and trachoma to the change in SCR cannot be fully assessed.
No currently available serological test distinguishes between exposure to ocular and urogenital CT infection. 
It is interesting to note that the seroprevalence among 10–19-year-old Gambian females in our study was almost 
double that of their male counterparts of the same age. In the Gambia, the median age at which females first have 
sex is 18.6 years, with 52% of women aged 20–24 years surveyed as part of the Demographic and Health Survey 
(2013) having had sexual intercourse by age 20. In males the median age is 23.1 years, with 48% of men aged 
25–29 years surveyed having had sexual intercourse by age 2238. This could in part explain why we observed a 
gender difference in seroprevalence in the 10–19-year-old age range, as those with earlier sexual debut would be 
expected to be more likely to acquire STIs39–41 and to seroconvert.
In a population in which the urogenital Ct infection prevalence has been consistently low, it might be expected 
that anti-Pgp3 serological data would more accurately reflect longitudinal trends in ocular Ct transmission. 
Whilst data suggest that the prevalence of urogenital Ct infections has historically been very low in rural areas 
of The Gambia42,43, there are no recent data, nor data based on modern molecular testing methods. A 2003 study 
from Malicounda in Thiès Region of neighbouring Senegal estimated that the prevalence of urogenital Ct infec-
tion there was just 0.3% (n = 73)44. A systematic review of global estimates of incidence and prevalence of sex-
ually transmitted infections (STI), including urogenital chlamydia, estimated that the prevalence of urogenital 
chlamydia was 2.9% in low-income countries45, although it is noted that this study did not include data from The 
Gambia.
Figure 4. Expected seroprevalence curves as function of age (solid lines) according to the maximum likelihood 
estimates and the respective 95% confidence intervals (dashed lines) according to the best models selected 
in Fig. 3. The dots represent the observed seroprevalence when the age distribution was broken down in the 
respective deciles and the vertical pointed line refers to the change point estimated by the profile likelihood 
method.
Region
Prevalence of signs of trachoma
19866 19966
TT (≥30 year-olds)
201329
TT (≥15 year-olds)TF/TI (0–14 year-olds) TF/TI (0–9 year-olds) TF (0–9 year-olds)
Lower River Region 12.3% 11.5% 4.6% 1.8% 1.0%
Upper River Region 5.0% 1.3% 1.3% 0.4% 0.07%
Table 5. Previously published data on the prevalence active trachoma and trachomatous trichiasis, Lower 
River Region and Upper River Region, The Gambia, 1986–2013. Data from the 1986 survey was not available 
for 0–9 year olds, thus we have used the data for 0–14 year olds. TF = trachomatous inflammation - follicular, 
TI = trachomatous inflammation - intense, TT = trachomatous trichiasis.
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The cross-specificity of serological tests for antibodies emerging in response to ocular and urogenital Ct infec-
tions is a substantial hurdle that will need to be overcome if serological tests are to be widely deployed for tra-
choma monitoring.
The confidence intervals associated with SCRs seen in Fig. 4 are very broad (which in part reflects the uncer-
tainty of modelling approaches) and comparison between the charts for LRR and URR is indicative but not 
conclusive of a difference in SCR between the two regions. Although a larger sample size would reduce the uncer-
tainty, interpretation of the model depends to a large extent on the magnitude of the change as well as the timing 
between the change in SCR and sample collection, as seen in malaria modelling work25. The very large sample 
sizes required of studies that could delineate SCR changes with high precision could be prohibitive. The analysis 
is further limited by the fact that the model assumes a memoryless property over time and the SCR models are 
defined as a function of the seroreversion rate, which not easily estimated from a single cross-sectional survey.
A recent serological study using samples from Tanzania15 examined the age-specific seroprevalence of 
anti-Pgp3 antibodies in a trachoma-endemic community that had received two rounds of high coverage azithro-
mycin MDA. The all-ages prevalence of ocular Ct infection had fallen from 9.5% to 0.1% two years after MDA46, 
and to 0% five years after MDA37, with a corresponding 11-fold decrease in SCR15. This change in infection 
prevalence occurred in a more defined (and probably narrower) timeframe than the one we have studied in The 
Gambia. This resulted in a more acute change in SCR, as has been demonstrated in malaria modelling exer-
cises26,47. Previous trachoma modelling studies suggest that an individual may require upwards of 100 lifetime 
ocular Ct infections in order to develop TT48, so even a modest reduction in transmission may have significant 
public health implications and reduce the future incidence of TT.
Research is ongoing to address remaining challenges in interpreting trachoma seroprevalence. It is unclear 
how many infections are required for seroconversion to occur. Studies involving urogenital Ct infection suggest 
that just 68% of infected women produce IgG antibodies against Ct49. The intensity of the inflammatory response, 
and the surface area of inflamed mucosa, however, are both likely to differ between the infected conjunctiva and 
infected female urogenital tract. Additionally, further work is needed to determine the half-life of Pgp3 antibod-
ies and seroreversion rates. A previous study that examined a high-prevalence community before and after one 
round of azithromycin suggested that individual anti-Pgp3 antibody levels decreased slightly six months after 
drug treatment, but not enough to be considered seroreversion50. This is similar to results seen for urogenital 
Ct infection, where anti-Pgp3 antibody titres decreased over 4–7 years, but patients were still in the seropositive 
range51. Although we have estimated SRR in this study (Table 4), a more accurate estimate could be obtained 
from a longitudinal study collecting serum samples over a period of years. In low transmission settings, such as 
post-MDA communities, the SRR may be under-estimated if the assumption of a balance between total number 
of seropositive and seronegative individuals does not hold true. Further studies to determine SRR are currently 
underway.
Dichotomising antibody levels to a simple seropositive/seronegative classification provides a straightforward 
estimation of seroprevalence, but SCR estimates could potentially be improved by using a model based on anti-
body levels and multiple sampling time points, as suggested by Yman et al.52. Such models might assume that 
antibody levels increase with age, as exposure is age-dependent and that transmission intensity can be calculated 
by measuring the boost in antibody levels. The use of age group-specific geometric mean antibody levels could be 
explored52 in addition to SCR.
Approximately 4% of 1–9-year-olds were positive for antibodies to Pgp3, which may be due to previously 
acquired ocular Ct infections and/or to ocular or respiratory Ct infections acquired at birth from mothers with 
urogenital Ct infections53. This seroprevalence is within the range of prevalence values previously estimated in 
post-MDA surveys in Tanzania and Nepal14,15. There was also no observed increase in anti-Pgp3 antibody pos-
itivity with age in 1–9-year-olds (Supplementary Table 2), in contrast to what is observed in trachoma-endemic 
settings, whether treatment-naive18 or after 3 rounds of MDA17,21 and is in stark contrast to communities with a 
high prevalence of ocular infection16. Focusing on age-specific changes in seropositivity as a measure of cumula-
tive exposure to ocular Ct infection might offset antibody responses from peri-natal infection, as the latter would 
be expected to be consistent across all ages, or even to decline with increasing age. The data from The Gambia 
presented here, combined with those from a variety of pre- and post-MDA settings, contribute to an understand-
ing of the potential use of antibody-based surveillance of children to ensure a lack of infection recrudescence.
Data from paired pre- and post-MDA surveys, or longitudinal data from MDA surveys, would substantially 
improve parameters and modeling efforts. A detailed series of surveys in one population would help to develop 
generalized models for use elsewhere. The inclusion of infection data for both ocular and urogenital Ct infection 
is needed to further clarify how urogenital Ct contributes to observed seropositivity rates.
Methods
Ethical Review. This study was conducted in accordance with the Declaration of Helsinki. It received 
approval from the London School of Hygiene & Tropical Medicine Ethics Committee (LSHTM; reference 7059) 
and The Gambia Government/Medical Research Council Joint Ethics Committee (SCC1408v2). CDC investiga-
tors did not engage with study participants.
Survey methodology. We conducted a population-based, cluster-random-sampled survey was conducted 
in February-March 2014. The Gambia is divided into geographically-defined census Enumeration Areas (EAs) of 
approximately 600–800 people each. Sampling by EA is equivalent to sampling settlements with probability pro-
portional to their size54. Twenty EAs in each of URR and LRR were randomly selected for participation. Trained 
field workers sensitised villagers and obtained verbal community-consent from each village chief (alkalo). Field 
workers and alkalos compiled a list of households for each EA, from which households were randomly selected 
for census and recruitment. The study and consent form were explained to the head of each selected household 
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and prospective participants. All members of selected households were invited to participate, regardless of age. 
Written (thumbprint or signature) consent was obtained from each participant aged ≥18 years, while a parent or 
guardian provided written consent for each participating child aged under 18 years. Children aged 12–17 years 
provided assent before participating.
The trachoma graders were experienced in field grading for active trachoma and had received regular training 
according to PRET7 and Global Trachoma Mapping Project (GTMP) protocols55,56. After informed consent was 
received, the grader examined both eyes of the subject using a binocular loupe (2.5×) and a torch. The grader 
changed gloves between each participant to minimise the risk of carry-over infection. In accordance with the 
Gambian NEHP policy, antibiotics were provided to individuals with evidence of active trachoma and to residents 
of their household.
Each participant had a finger-prick blood sample collected onto filter paper (Trop-Bio, Townsville, Australia) 
using a sterile single-use lancet (BD Microtrainer, Dublin, Ireland). Each filter paper had six extensions, cali-
brated to absorb 10 µL of blood each. Samples were air-dried for approximately five hours and then placed in indi-
vidual Whirl-Pak plastic bags (Nasco, Modesto, California) which were stored with desiccant sachets (Whatman, 
Little Chalfont, UK) at −20 °C. All samples were shipped to LSHTM for testing.
ELISA Assay. Dried blood spots (DBS) were tested for antibodies against Pgp3 according to the method 
previously described21. Briefly, serum was eluted from dried blots spots then applied to a plate coated with Pgp3 
protein17; known standards were included and assayed in triplicate on each plate. Following incubation, bound 
antibody was detected with HRP-labelled mouse anti-human IgG(Fc)-HRP (Southern Biotech, Birmingham, 
USA). Plates were incubated and washed, and then TMB (KPL, Gaithersburg, USA) was added to develop the 
plates. The reaction was stopped with 1 N H2SO4 and optical density was read at 450 nm (OD450) on a Spectramax 
M3 plate reader (Molecular Devices, Wokingham UK). Readings were corrected for background by subtract-
ing the average absorbance of three blank wells containing no serum, using Softmax Pro5 software (Molecular 
Devices).
Statistical Methods. Blanked OD450 values for samples were normalised against the 200 U standard included 
on each plate21. Laboratory work was undertaken masked to demographic and clinical information. Statistical 
analyses were carried out using R57. Using the “survey” package and assuming a design effect of 2.6555, the 95% 
confidence intervals (CI) were calculated using the Clopper-Pearson interval58. Wilcoxon-Mann-Whitney 
z-scores59 were calculated to compare the proportion seropositive between different regions, ages, and genders. 
The non-parametric test for trend was used to measure the increase in prevalence of anti-Pgp3 antibodies with age.
A finite mixture model25 was used to classify the samples as seropositive or seronegative based on normalised 
OD450 values. The data were fitted using maximum likelihood methods, estimating the distribution parameters for 
each classification group (assumed seropositive or assumed seronegative) as well as the proportion of samples in 
each category to fit the overall distribution of results60. To ensure that the assay had high specificity, the threshold 
for seropositivity was set using the mean of the Gaussian distribution of the seronegative population plus four 
standard deviations (the quantile inclusive of 99.994%) of the seronegative population25,60.
Population age groups were categorized according to known time points of changes in disease prevalence. 
The youngest age group was 1–9-year-olds, who in LRR are likely to have been born during or after MDA with 
azithromycin. The oldest group included people aged 40 years and above, who experienced secular declines in tra-
choma prevalence prior to 1986, the year of the first National Survey of Blindness and Low Vision6. Participants 
aged between 10 and 39 years were grouped into 10-year categories.
Different reversible catalytic models were applied to the analysis of the data from each region. These models 
are described as function of seroconversion and seroreversion rates (SCR and SRR, respectively). SCR is defined 
as the annual mean rate by which seronegative individuals become seropositive upon disease exposure and is 
usually considered as a proxy of the transmission intensity of the population. SRR describes the annual mean rate 
by which seropositive individuals revert to a seronegative status in the absence of re-infection. Three reversible 
catalytic models were fit to the serological data of each region: (i) a simple model that assumes a constant SCR 
(i.e., transmission intensity) over time and people are born seronegative27; (ii) a model with a constant historical 
SCR until a certain change point in the past where SCR changes abruptly to a new value (current SCR); (iii) a 
model that also assumes a historical seroconversion rate until a certain change point followed by a time period 
where SCR decays log-linearly every year. The respective parameter estimation was done using maximum likeli-
hood principles. In particular, the models assuming a change point were estimated via profile likelihood method, 
as described elsewhere25. Model comparison for the data of each region was based on the Akaike’s information 
criterion where the best model (and change point) is the one that provides the minimum estimate of this statistics.
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